Emapalumab’s efficacy confirmed by sensitivity analysis presented at ESID2020
· Treatment goal in primary haemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening disorder, is to stabilise the disease and bring patients to haematopoietic stem cell transplantation (HSCT), the only curative therapy · Unmet medical need remains high, with current standard-of-care therapy associated with adverse events and no decrease in mortality rates in the past 20 years · Pivotal study of emapalumab in primary HLH patients who had no satisfactory response to prior treatments, was the first HLH study to use clinically objective response criteria · Data from